Research Synthesis: Resveratrol Effects

Research Synthesis: Resveratrol Effects

Abstract

Evidence-honesty note: 31/61 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 53/61 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on resveratrol effects across 61 included source papers and 2515 high-confidence extracted claims.

The evidence profile contains 8 direct clinical sources, 21 adjacent clinical sources, and 1 mechanistic or model-system source, with 491 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the immune outcome class; null signals are summarized in the contextual adjacent evidence, dosing and pharmacokinetics, safety and comorbidity, skeletal, fracture, and bone, deficiency prevalence, and muscle function outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic, frailty, immune and inflammation, and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that resveratrol effects should be treated as a bounded geroscience hypothesis: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-resveratrol_effects-v06-DAILY-2026-06-14T08-15-12Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-14.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• resveratrol effects aging
• resveratrol effects older adults
• resveratrol effects randomized controlled trial
• resveratrol aging
• resveratrol older adults
• resveratrol randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses resveratrol effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 181 records in the receipt-candidate union, 61 were classified as source candidates and 61 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	181
Classified source candidates	61
No extractable claims	16
None-only claim binding	3
Mixed partial-or-none claim-binding candidates	46
Partial-only claim-binding candidates	22
Strict high-confidence sources	33
Admitted final sources	61

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, frailty, immune, immune and inflammation, longevity, muscle function, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=20; claims=1137	no extracted directional signal in 14/20 sources	2 direct; 9 indirect; 9 review	limited corpus depth in this outcome class
Dosing and Pharmacokinetics	n=12; claims=805	no extracted directional signal in 6/12 sources	5 indirect; 7 review	limited corpus depth in this outcome class
Cardiometabolic	n=10; claims=160	positive signal in 4/10 sources	2 direct; 2 indirect; 6 review	limited corpus depth in this outcome class
Immune	n=6; claims=103	positive signal in 3/6 sources	2 direct; 1 indirect; 3 review	limited corpus depth in this outcome class
Frailty	n=3; claims=3	unclear signal in 2/3 sources	1 direct; 2 review	limited corpus depth in this outcome class
Immune and Inflammation	n=3; claims=150	unclear signal in 2/3 sources	1 direct; 2 indirect	limited corpus depth in this outcome class
Safety and Comorbidity	n=2; claims=70	no extracted directional signal in 2/2 sources	2 review	limited corpus depth in this outcome class
Skeletal, Fracture, and Bone	n=2; claims=42	no extracted directional signal in 2/2 sources	1 indirect; 1 review	limited corpus depth in this outcome class
Population / prevalence	n=1; claims=21	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Longevity	n=1; claims=4	unclear signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Muscle Function	n=1; claims=20	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

20 included sources were assigned to this outcome class. Directional coding: mixed=2, null=14, positive=2, unclear=2. Directness coding: direct=2, indirect=9, review=9.

Dose / exposure Outcomes

12 included sources were assigned to this outcome class. Directional coding: negative=1, null=6, positive=2, unclear=3. Directness coding: indirect=5, review=7.

Cardiometabolic Outcomes

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

Frailty Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=1, unclear=2. Directness coding: direct=1, review=2.

Immune Inflammation Outcomes

3 included sources were assigned to this outcome class. Directional coding: negative=1, unclear=2. Directness coding: direct=1, indirect=2.

Safety Comorbidity Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2.

Skeletal Fracture Bone Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=1, review=1.

Population / prevalence Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Longevity Outcomes

1 included source were assigned to this outcome class. Directional coding: unclear=1. Directness coding: review=1.

Muscle Function Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

A key limitation of this synthesis is the absence of long-term mortality trials in the curated corpus, which precludes any conclusion about resveratrol’s impact on hard clinical endpoints in humans. The corpus is dominated by mechanistic and biomarker-focused studies, including preclinical systematic reviews (e.g., Li 2026) and human RCTs with intermediate endpoints such as inflammatory markers or metabolic profiles (e.g., Zhou 2023, Montoya-Estrada 2024). While these outcomes provide insight into biological plausibility, they do not establish whether resveratrol influences survival or disease progression over time. Without trials explicitly designed to evaluate mortality or major morbidity events, the external validity of the current evidence base remains constrained to surrogate domains.

The evidence base is further constrained by the single-trial representation for several outcome classes, which limits the robustness of any pooled inferences and increases the risk of overgeneralization. For example, only one source (Dogan 2024) addresses ulcerative colitis outcomes, and its positive findings are not replicated within the corpus. Similarly, the skeletal fracture and bone outcomes are represented by a single review (Corbi 2023) with indirect evidence, leaving no clinical trial to corroborate its mechanistic claims. This single-trial dependency undermines the synthesis’s ability to distinguish true effects from idiosyncratic trial findings or publication bias, particularly in domains where no additional human data exist.

Population specificity is a critical limitation, as the enrolled cohorts skew heavily toward adults with metabolic or inflammatory conditions, leaving substantial gaps in generalizability to broader populations. Additionally, no trials explicitly enrolled individuals with sarcopenic obesity despite the mechanistic plausibility of resveratrol in this phenotype (Russo 2026). This narrow demographic focus restricts the applicability of conclusions to the broader adult population, particularly those with multimorbidity or advanced age.

Endpoint scope is another major limitation, as the corpus omits critical clinical outcomes that would be necessary to evaluate resveratrol’s therapeutic potential. No trials in the curated set assess hard endpoints such as cardiovascular events, stroke, or cancer incidence, despite mechanistic evidence suggesting potential benefits in these areas (e.g., Nyambuya 2020, Molani-Gol 2024). Similarly, there is a paucity of data on functional outcomes like mobility, activities of daily living, or quality of life in non-frail populations, with only qualitative evidence available for some domains (e.g., Hecker 2021). The reliance on surrogate biomarkers, such as inflammatory markers or bone turnover indices, limits the clinical interpretability of the findings and leaves uncertainty about whether observed biological changes translate into meaningful patient-centered outcomes.

A fundamental mechanism-to-clinic gap persists, particularly in domains where mechanistic evidence is robust but clinical translation is sparse or conflicting. For instance, preclinical meta-analyses demonstrate consistent reductions in oxidative stress and inflammation with resveratrol supplementation (e.g., Li 2026, Lv 2025), yet human RCTs in similar mechanistic domains often report null or mixed findings (e.g., Nikniaz 2023, SHEN 2026). This disconnect suggests that factors such as bioavailability, dosing regimens, or population heterogeneity may critically mediate the translation of mechanistic effects into clinical benefits. Without trials specifically designed to bridge this gap—such as those incorporating pharmacokinetic-guided dosing or mechanistic stratification—the synthesis cannot resolve whether the observed preclinical signals are clinically actionable.

Conclusion

For resveratrol effects, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 61 included sources on Resveratrol Effects across 11 outcome classes and 491 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 61 curated reference papers, the evidence base for Resveratrol Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, immune. Negative signals appear in: immune, dosing pharmacokinetics. Null findings dominate: contextual other, dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Resveratrol Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the disagreement between Zhu 2025 and SHEN 2026 on dosing and pharmacokinetics (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

In animal/preclinical evidence, prior reviews in the corpus (Li 2026, Lv 2025, Zhu 2025, Nyambuya 2020, Xiao 2025) emphasize convergent signals on Resveratrol Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	1	unclear	direct interventional hard-endpoint gap
muscle function	0	1	null	direct interventional hard-endpoint gap
cardiometabolic	2	8	mixed, null, positive, unclear	conflict-resolution gap
frailty	1	2	null, unclear	replication gap
deficiency prevalence	0	1	null	direct interventional hard-endpoint gap
dosing and pharmacokinetics	0	12	negative, null, positive, unclear	conflict-resolution gap
immune	2	4	mixed, negative, positive	conflict-resolution gap
safety and comorbidity	0	2	null	direct interventional hard-endpoint gap
skeletal, fracture, and bone	0	2	null	direct interventional hard-endpoint gap
contextual adjacent evidence	2	18	mixed, null, positive, unclear	conflict-resolution gap
immune and inflammation	1	2	negative, unclear	replication gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear
P2	muscle function: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P3	cardiometabolic: conflict-resolution gap	2 direct and 8 indirect sources; direction profile: mixed, null, positive, unclear
P4	frailty: replication gap	1 direct and 2 indirect sources; direction profile: null, unclear
P5	deficiency prevalence: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Resveratrol Effects should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Additional corpus sources included animal/preclinical evidence; Zhou 2023; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.01.
• Montoya-Estrada 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P = 0.0001.
• Ma 2022; tier=A1; directness=direct; endpoint=immune inflammation; direction=unclear; representative statistic=P < 0.01.
• Bastin 2025; tier=A1; directness=direct; endpoint=immune; direction=negative; representative statistic=P = 0.001.
• Zaw 2021; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.001.
• Boswijk 2022; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null.
• Keramatzadeh 2025; tier=A1; directness=direct; endpoint=immune; direction=positive; representative statistic=P < 0.001.
• Karim 2025; tier=A1; directness=direct; endpoint=frailty; direction=unclear; representative statistic=P < 0.05.
• Li 2026; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.001.
• Lv 2025; tier=B1; directness=review; endpoint=dosing pharmacokinetics; direction=positive; representative statistic=P < 0.00001.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=146.
• The Administration of Resveratrol and Vitamin C Reduces Oxidative Stress in Postmenopausal Women—A Pilot Randomized Clinical Trial: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=mixed; claims=80.
• Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol: outcome=immune inflammation; directness=direct; tier=A1; direction=unclear; claims=29.
• Effects of resveratrol on inflammatory cytokines in COVID-19 patients: a randomized, double-blinded, placebo-controlled clinical trial.: outcome=immune; directness=direct; tier=A1; direction=negative; claims=9.
• Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study.: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=5.
• Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: a randomized crossover trial.: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=2.
• Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial.: outcome=immune; directness=direct; tier=A1; direction=positive; claims=2.
• Resveratrol treatment increases sirtuin 1 levels and alleviates frailty phenotype in knee osteoarthritis patients: a randomised placebo-controlled clinical trial.: outcome=frailty; directness=direct; tier=A1; direction=unclear; claims=1.
• Protective effect and possible mechanisms of resveratrol in animal models of spinal cord injury: a preclinical systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=mixed; claims=195.
• A comprehensive and systematic review on resveratrol supplementation as a promising candidate for the retinal disease: a focus on mechanisms of action from preclinical studies: outcome=dosing pharmacokinetics; directness=review; tier=B1; direction=positive; claims=71.
• The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis: outcome=dosing pharmacokinetics; directness=review; tier=B1; direction=positive; claims=53.
• A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=48.
• Therapeutic effects and safety of resveratrol for lung cancer: an updated preclinical systematic review and meta-analysis: outcome=safety comorbidity; directness=review; tier=B1; direction=null; claims=24.
• Efficacy and safety of dietary polyphenol supplements for COPD: a systematic review and meta-analysis: outcome=immune; directness=review; tier=B1; direction=mixed; claims=18.
• Effects of resveratrol on the anthropometric indices and inflammatory markers: an umbrella meta-analysis.: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=12.
• Resveratrol and metabolic health in COPD: A proof-of-concept randomized controlled trial.: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=10.
• Resveratrol in diabetes and pancreatic function: implications for the exocrine–endocrine pancreatic axis–a systematic review: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=10.
• Pilot study of resveratrol in older adults with impaired glucose tolerance.: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=8.
• Effect of resveratrol on C-reactive protein: An updated meta-analysis of randomized controlled trials.: outcome=immune; directness=review; tier=B1; direction=positive; claims=8.
• A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=4.
• The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials.: outcome=immune; directness=review; tier=B1; direction=positive; claims=4.
• Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-Analysis.: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=2.
• Improvement in postural imbalance with intake of resveratrol (polyphenolic phytoalexin) in patients of knee osteoarthritis.: outcome=frailty; directness=review; tier=B1; direction=unclear; claims=1.
• Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=151.
• Resveratrol delays the progression of diabetic nephropathy through multiple pathways: A dose–response meta‐analysis based on animal models: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=119. Translational relevance to humans remains uncertain.
• Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=107.
• Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=92.
• Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease: outcome=immune inflammation; directness=indirect; tier=B2; direction=negative; claims=89.
• Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=negative; claims=89.
• Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=83.
• Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=unclear; claims=82.
• Effects of resveratrol on renal ischemia-reperfusion injury: A systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=72.
• A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=68.
• Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic periodontitis: a randomized clinical trail: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=65.
• Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam: outcome=immune; directness=indirect; tier=B2; direction=negative; claims=62.
• A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol ( Polygonum cuspidatum ), Luteolin, and Fisetin ( Rhus succedanea ): outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=56.
• Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=49.
• The anti-inflammatory activity of resveratrol in acute kidney injury: a systematic review and meta‐analysis of animal studies: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=46.
• Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=null; claims=41.
• Effects of Mediterranean Diet, Curcumin, and Resveratrol on Mild-to-Moderate Active Ulcerative Colitis: A Multicenter Randomized Clinical Trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=39.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Additional corpus sources included animal/preclinical evidence; severity 5 disagreement: Zhu 2025 vs SHEN 2026; Zhu 2025 reports positive effect on dosing pharmacokinetics; SHEN 2026 reports negative on the same outcome — direct conflict
• Severity 5 disagreement: Lv 2025 vs SHEN 2026; Lv 2025 reports positive effect on dosing pharmacokinetics; SHEN 2026 reports negative on the same outcome — direct conflict
• Severity 5 disagreement: Marouf 2021 vs Tabrizi 2018; Marouf 2021 reports negative effect on immune; Tabrizi 2018 reports positive on the same outcome — direct conflict
• Severity 5 disagreement: Marouf 2021 vs Gorabi 2021; Marouf 2021 reports negative effect on immune; Gorabi 2021 reports positive on the same outcome — direct conflict
• Severity 5 disagreement: Keramatzadeh 2025 vs Bastin 2025; Keramatzadeh 2025 reports positive effect on immune; Bastin 2025 reports negative on the same outcome — direct conflict
• Severity 4 null vs positive: Nikniaz 2023 vs Zhu 2025; Zhu 2025 (positive on dosing pharmacokinetics) vs Nikniaz 2023 (null on dosing pharmacokinetics) — partial conflict
• Severity 4 null vs positive: Nikniaz 2023 vs Lv 2025; Lv 2025 (positive on dosing pharmacokinetics) vs Nikniaz 2023 (null on dosing pharmacokinetics) — partial conflict
• Severity 4 null vs positive: Nikniaz 2023 vs SHEN 2026; SHEN 2026 (negative on dosing pharmacokinetics) vs Nikniaz 2023 (null on dosing pharmacokinetics) — partial conflict

Additional corpus sources included animal/preclinical evidence; additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Li 2021, Liu 2024, Garcia-Martinez 2023, Wu 2025, Moussa 2017, Fadlalmola 2023, Wong 2020, Lan 2023, Turner 2015, Hodgin 2021, Jardon 2024, Cao 2022, Movahed 2020, Goncalinho 2021, Rao 2025, Wang 2025, Yin 2025, Liu 2025, Sangouni 2022, Jin 2023, Zhang 2022, Rabbani 2021, Evans 2016, Marouf 2021b, Ferreira 2020, Wu 2025b, Samaei 2020, Brown 2024, Meden 2026, Beijers 2020, Barbarino 2022, Crandall 2012, Tan 2022, Wei 2024, Hu 2021, Miao 2025, Shuid 2025, Karim 2026, Studenski 2011, Cruz-Jentoft 2019, Ioannidis 2005.

References

• Li 2026. Protective effect and possible mechanisms of resveratrol in animal models of spinal cord injury: a preclinical systematic review and meta-analysis. Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1853441. PMID: 42254029.
• Li 2021. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials. BMC Complementary Medicine and Therapies, 2021. DOI: 10.1186/s12906-021-03381-4. PMID: 34420523.
• Zhou 2023. A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia. Nutrients, 2023. DOI: 10.3390/nu15030492. PMID: 36771199.
• Liu 2024. Resveratrol delays the progression of diabetic nephropathy through multiple pathways: A dose–response meta‐analysis based on animal models. Journal of Diabetes, 2024. DOI: 10.1111/1753-0407.13608. PMID: 39264004.
• Garcia-Martinez 2023. Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes. International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms24087422. PMID: 37108584.
• Wu 2025. Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis. Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1588284. PMID: 40771919.
• SHEN 2026. Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases. In Vivo, 2026. DOI: 10.21873/invivo.14235. PMID: 41760304.
• Moussa 2017. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. Journal of Neuroinflammation, 2017. DOI: 10.1186/s12974-016-0779-0. PMID: 28086917.
• Fadlalmola 2023. Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials. The Pan African Medical Journal, 2023. DOI: 10.11604/pamj.2023.44.134.32404. PMID: 37333786.
• Wong 2020. Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial. Journal of Bone and Mineral Research, 2020. DOI: 10.1002/jbmr.4115. PMID: 32564438.
• Montoya-Estrada 2024. The Administration of Resveratrol and Vitamin C Reduces Oxidative Stress in Postmenopausal Women—A Pilot Randomized Clinical Trial. Nutrients, 2024. DOI: 10.3390/nu16213775. PMID: 39519608.
• Lan 2023. Effects of resveratrol on renal ischemia-reperfusion injury: A systematic review and meta-analysis. Frontiers in Nutrition, 2023. DOI: 10.3389/fnut.2022.1064507. PMID: 36687723.
• Lv 2025. A comprehensive and systematic review on resveratrol supplementation as a promising candidate for the retinal disease: a focus on mechanisms of action from preclinical studies. Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1615910. PMID: 40717982.
• Turner 2015. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology, 2015. DOI: 10.1212/WNL.0000000000002035. PMID: 26362286.
• Nikniaz 2023. Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic periodontitis: a randomized clinical trail. BMC Oral Health, 2023. DOI: 10.1186/s12903-023-02877-4. PMID: 36973728.
• Marouf 2021. Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam. Indian Journal of Pharmacology, 2021. DOI: 10.4103/ijp.IJP_493_20. PMID: 34414904.
• Hodgin 2021. A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol ( Polygonum cuspidatum ), Luteolin, and Fisetin ( Rhus succedanea ). International Journal of Environmental Research and Public Health, 2021. DOI: 10.3390/ijerph18052483. PMID: 33802381.
• Zhu 2025. The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis. Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2024.1463027. PMID: 39872318.
• Jardon 2024. Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity. Gut Microbes, 2024. DOI: 10.1080/19490976.2024.2392875. PMID: 39182247.
• Nyambuya 2020. A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy. Molecules, 2020. DOI: 10.3390/molecules25235645. PMID: 33266114.
• Cao 2022. The anti-inflammatory activity of resveratrol in acute kidney injury: a systematic review and meta‐analysis of animal studies. Pharmaceutical Biology, 2022. DOI: 10.1080/13880209.2022.2132264. PMID: 36269038.
• Corbi 2023. Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial. International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms241512063. PMID: 37569440.
• Dogan 2024. Effects of Mediterranean Diet, Curcumin, and Resveratrol on Mild-to-Moderate Active Ulcerative Colitis: A Multicenter Randomized Clinical Trial. Nutrients, 2024. DOI: 10.3390/nu16101504. PMID: 38794742.
• Movahed 2020. Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial. Nutrients, 2020. DOI: 10.3390/nu12010161. PMID: 31935938.
• Goncalinho 2021. Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial. Molecules, 2021. DOI: 10.3390/molecules26113168. PMID: 34073163.
• Rao 2025. Trans-resveratrol reduces visible signs of skin ageing in healthy adult females over 40: an 8-week randomized placebo-controlled trial. Frontiers in Aging, 2025. DOI: 10.3389/fragi.2025.1727244. PMID: 41488277.
• Wang 2025. Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects. Scientific Reports, 2025. DOI: 10.1038/s41598-025-08665-0. PMID: 40628835.
• Yin 2025. Protective effects and mechanism of resveratrol in animal models of pulmonary fibrosis: a preclinical systematic review and meta-analysis. Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1666698. PMID: 41089832.
• Liu 2025. Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer’s Disease. International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26115044. PMID: 40507855.
• Sangouni 2022. Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial. BMC Cardiovascular Disorders, 2022. DOI: 10.1186/s12872-022-02637-2. PMID: 35538431.
• Jin 2023. Evidence of Clinical Efficacy and Pharmacological Mechanisms of Resveratrol in the Treatment of Alzheimer’s Disease. Current Alzheimer Research, 2023. DOI: 10.2174/0115672050272577231120060909. PMID: 38047366.
• Zhang 2022. Resveratrol decreases local inflammatory markers and systemic endotoxin in patients with aggressive periodontitis. Medicine, 2022. DOI: 10.1097/MD.0000000000029393. PMID: 35758374.
• Ma 2022. Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol. Medicine, 2022. DOI: 10.1097/MD.0000000000030049. PMID: 35960095.
• Rabbani 2021. Reversal of Insulin Resistance in Overweight and Obese Subjects by trans -Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation. Nutrients, 2021. DOI: 10.3390/nu13072374. PMID: 34371884.
• Hecker 2021. The impact of resveratrol on skin wound healing, scarring, and aging. International Wound Journal, 2021. DOI: 10.1111/iwj.13601. PMID: 33949795.
• Evans 2016. Clinical Evaluation of Effects of Chronic Resveratrol Supplementation on Cerebrovascular Function, Cognition, Mood, Physical Function and General Well-Being in Postmenopausal Women—Rationale and Study Design. Nutrients, 2016. DOI: 10.3390/nu8030150. PMID: 27005658.
• Xiao 2025. Therapeutic effects and safety of resveratrol for lung cancer: an updated preclinical systematic review and meta-analysis. Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1644538. PMID: 40948874.
• Marouf 2021b. Effect of Resveratrol on Serum Levels of Type II Collagen and Aggrecan in Patients with Knee Osteoarthritis: A Pilot Clinical Study. BioMed Research International, 2021. DOI: 10.1155/2021/3668568. PMID: 34805399.
• Ferreira 2020. Dose-related Effects of Resveratrol in Different Models of Pulmonary Arterial Hypertension: A Systematic Review. Current Cardiology Reviews, 2020. DOI: 10.2174/1573403X15666191203110554. PMID: 31797762.
• Wu 2025b. Efficacy and safety of dietary polyphenol supplements for COPD: a systematic review and meta-analysis. Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1617694. PMID: 40771814.
• Samaei 2020. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial. International Journal of Neuropsychopharmacology, 2020. DOI: 10.1093/ijnp/pyaa006. PMID: 33372679.
• Molani-Gol 2024. Effects of resveratrol on the anthropometric indices and inflammatory markers: an umbrella meta-analysis. Eur J Nutr, 2024. DOI: 10.1007/s00394-024-03335-9. PMID: 38374352.
• Brown 2024. Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities. International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms25020747. PMID: 38255828.
• Meden 2026. Resveratrol in diabetes and pancreatic function: implications for the exocrine–endocrine pancreatic axis–a systematic review. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1806881. PMID: 42099770.
• Beijers 2020. Resveratrol and metabolic health in COPD: A proof-of-concept randomized controlled trial. Clin Nutr, 2020. DOI: 10.1016/j.clnu.2020.01.002. PMID: 31996311.
• Barbarino 2022. Integrative skincare trial of intense pulsed light followed by the phyto‐corrective mask, phyto‐corrective gel, and resveratrol BE for decreasing post‐procedure downtime and improving procedure outcomes in patients with rosacea. Journal of Cosmetic Dermatology, 2022. DOI: 10.1111/jocd.15189. PMID: 35765796.
• Bastin 2025. Effects of resveratrol on inflammatory cytokines in COVID-19 patients: a randomized, double-blinded, placebo-controlled clinical trial. Mol Cell Biochem, 2025. DOI: 10.1007/s11010-025-05290-3. PMID: 40301181.
• Crandall 2012. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci, 2012. DOI: 10.1093/gerona/glr235. PMID: 22219517.
• Gorabi 2021. Effect of resveratrol on C-reactive protein: An updated meta-analysis of randomized controlled trials. Phytother Res, 2021. DOI: 10.1002/ptr.7262. PMID: 34472150.
• Tan 2022. Efficacy of Resveratrol in Experimental Subarachnoid Hemorrhage Animal Models: A Stratified Meta-Analysis. Frontiers in Pharmacology, 2022. DOI: 10.3389/fphar.2022.905208. PMID: 35847035.
• Zaw 2021. Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study. Clin Nutr, 2021. DOI: 10.1016/j.clnu.2020.08.025. PMID: 32900519.
• Wei 2024. Resveratrol’s bibliometric and visual analysis from 2014 to 2023. Frontiers in Plant Science, 2024. DOI: 10.3389/fpls.2024.1423323. PMID: 39439517.
• Hu 2021. A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities. Oxidative Medicine and Cellular Longevity, 2021. DOI: 10.1155/2021/2951697. PMID: 34471463.
• Tabrizi 2018. The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Food Funct, 2018. DOI: 10.1039/c8fo01259h. PMID: 30426122.
• Boswijk 2022. Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: a randomized crossover trial. Nuklearmedizin, 2022. DOI: 10.1055/a-1585-7215. PMID: 34918332.
• Keramatzadeh 2025. Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial. Nutr Neurosci, 2025. DOI: 10.1080/1028415x.2024.2425649. PMID: 39565038.
• Miao 2025. Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-Analysis. Phytother Res, 2025. DOI: 10.1002/ptr.8431. PMID: 40439602.
• Shuid 2025. A Systematic Review on the Molecular Mechanisms of Resveratrol in Protecting Against Osteoporosis. International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26072893. PMID: 40243497.
• Russo 2026. Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1818450. PMID: 42221760.
• Karim 2025. Resveratrol treatment increases sirtuin 1 levels and alleviates frailty phenotype in knee osteoarthritis patients: a randomised placebo-controlled clinical trial. Int J Food Sci Nutr, 2025. DOI: 10.1080/09637486.2025.2563670. PMID: 40990472.
• Karim 2026. Improvement in postural imbalance with intake of resveratrol (polyphenolic phytoalexin) in patients of knee osteoarthritis. Explore (NY), 2026. DOI: 10.1016/j.explore.2026.103341. PMID: 41679011.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.